.Attribute Medication, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA study, after a median follow-up of 11 months, clients along with metastatic stomach cysts that received biomarker-matched therapies based on circulating growth DNA profiling presented a better clinical benefit than those obtaining unparalleled therapy.